Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)
Immunome, Inc. (NASDAQ: IMNM) is in the spotlight on December 16, 2025, after the company reported positive topline Phase 3 results for its lead desmoid tumor program and then moved to raise significant new capital—two catalysts that can push a